BB&T Securities LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 1.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,313,081 shares of the biopharmaceutical company’s stock after selling 35,717 shares during the period. Pfizer accounts for 1.3% of BB&T Securities LLC’s portfolio, making the stock its 6th largest position. BB&T Securities LLC’s holdings in Pfizer were worth $81,443,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in PFE. Kelman Lazarov Inc. purchased a new stake in shares of Pfizer during the first quarter worth approximately $501,000. GW&K Investment Management LLC boosted its stake in shares of Pfizer by 4.6% in the first quarter. GW&K Investment Management LLC now owns 959,019 shares of the biopharmaceutical company’s stock worth $28,425,000 after buying an additional 41,757 shares during the period. Narwhal Capital Management boosted its stake in shares of Pfizer by 1.4% in the first quarter. Narwhal Capital Management now owns 125,322 shares of the biopharmaceutical company’s stock worth $3,715,000 after buying an additional 1,700 shares during the period. Boston Advisors LLC boosted its stake in shares of Pfizer by 0.4% in the first quarter. Boston Advisors LLC now owns 619,828 shares of the biopharmaceutical company’s stock worth $18,372,000 after buying an additional 2,606 shares during the period. Finally, Regent Investment Management LLC boosted its stake in shares of Pfizer by 77.8% in the first quarter. Regent Investment Management LLC now owns 33,768 shares of the biopharmaceutical company’s stock worth $1,001,000 after buying an additional 14,781 shares during the period. 69.66% of the stock is owned by hedge funds and other institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.31% during trading on Friday, hitting $32.66. The stock had a trading volume of 15,569,339 shares. The company has a 50-day moving average of $34.02 and a 200 day moving average of $34.27. The firm has a market cap of $198.10 billion, a P/E ratio of 28.95 and a beta of 0.86. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. During the same period last year, the firm earned $0.56 EPS. Pfizer’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.67%. Pfizer’s dividend payout ratio is currently 95.24%.
Several brokerages recently issued reports on PFE. Vetr cut Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 target price on the stock. in a research report on Thursday. Jefferies Group cut Pfizer from a “buy” rating to a “hold” rating and cut their target price for the company from $39.00 to $36.00 in a research report on Thursday. Argus reaffirmed a “buy” rating and set a $39.00 target price on shares of Pfizer in a research report on Tuesday, October 4th. Bank of America Corp. reaffirmed a “buy” rating and set a $40.00 target price on shares of Pfizer in a research report on Tuesday, September 27th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Eleven analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.